No Link Between Telomere Length and Diabetes Risk

This article originally appeared here.
Share this content:
No Link Between Telomere Length and Diabetes Risk
No Link Between Telomere Length and Diabetes Risk

(HealthDay News) -- Leukocyte telomere length is not independently associated with type 2 diabetes risk in postmenopausal women, according to a study published online July 24 in Diabetes.

Nai-chieh Y. You, from the University of California Los Angeles, and colleagues compared leukocyte telomere length in 1,675 postmenopausal women with type 2 diabetes and 2,382 matched controls, from the multiethnic Women's Health Initiative.

The researchers found that, after adjustment for matching and known diabetes risk factors, the odds ratios per one-kilobase increment ranged from 0.88 to 1.00 depending on ethnicity, and that none of the associations were significant. They identified 14 single nucleotide polymorphisms out of 80 examined in nine genes involved in telomere regulation that were predictive of telomere length, but none were significantly associated with diabetes, even when considering ethnic-specific single nucleotide polymorphisms.

"Although leukocyte telomere length was weakly associated with diabetes risk, this association was not independent of known risk factors," You and colleagues conclude. "These prospective findings indicate limited clinical utility of telomere length in diabetes risk stratification among postmenopausal women."

Abstract
Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs